Premium
Prodrugs of the Cytostatic CC‐1065 That Can Be Activated in a Tumor‐Selective Manner
Author(s) -
Tietze Lutz F.,
Hannemann Robert,
Buhr Wilm,
Lögers Michael,
Menningen Pia,
Lieb Monika,
Starck Dorothea,
Grote Thomas,
Döring Angela,
Schuberth Ingrid
Publication year - 1996
Publication title -
angewandte chemie international edition in english
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.831
H-Index - 550
eISSN - 1521-3773
pISSN - 0570-0833
DOI - 10.1002/anie.199626741
Subject(s) - prodrug , monoclonal antibody , cytotoxic t cell , conjugate , chemistry , stereochemistry , glycoside , derivative (finance) , cytotoxicity , pharmacology , biochemistry , antibody , biology , in vitro , immunology , mathematical analysis , mathematics , economics , financial economics
The O‐glycosides 1 of the seco‐CI derivative 2 , which is the seco form of the simplified pharmacophoric group of the potent cytotoxic antibiotic CC‐1065, show only very low toxicity. In tumor‐selective cancer therapy they can be used in conjunction with conjugates of glycohydrolases and monoclonal antibodies that bind at tumor‐associated antigens. The glycohydrolases cleave the prodrugs 1 and release the cytotoxic components 2 .